Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 14, 2019

SELL
$15.58 - $28.41 $578,173 - $1.05 Million
-37,110 Closed
0 $0
Q3 2018

Nov 13, 2018

SELL
$25.99 - $30.6 $646,111 - $760,716
-24,860 Reduced 40.12%
37,110 $1.05 Million
Q2 2018

Aug 13, 2018

BUY
$27.78 - $38.53 $1.72 Million - $2.39 Million
61,970 New
61,970 $1.75 Million

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $71M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Axiom Investors LLC Portfolio

Follow Axiom Investors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axiom Investors LLC , based on Form 13F filings with the SEC.

News

Stay updated on Axiom Investors LLC with notifications on news.